This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F80.3 | Special Copayment Reduction: V256 |
| B. Synonyms | Acquired epileptic aphasia, Landau-Kleffner syndrome (LKS), acquired aphasia with epilepsy, epileptic aphasia, acquired epileptic aphasia syndrome |
| C. Adult onset | Low likelihood of first onset in adulthood — mainly manifests in childhood at ages 2~12, and adult onset is very rare |
| 1. History | First described in 1957 by William M. Landau and Frank R. Kleffner: the clinical combination of acquired aphasia + epilepsy after normal language development |
| 2. Causes | Unclear; GRIN2A gene variants (about 20%); abnormal epileptic discharges in the temporo-parietal language cortex cause language dysfunction |
| 3. Genetics | Associated with heterozygous GRIN2A (16p13.2, NR2A subunit) variants; part of the GRIN2A-related epilepsy-aphasia spectrum disorders |
| 4. Epidemiology | Several hundred cases reported worldwide; a very rare disease affecting fewer than 1~2 per million, male predominance (male:female ≈ 2:1), age of onset 2~12 years |
| 5. Pathophysiology | Epileptiform discharges in the temporal language cortex → sustained cortical hyperexcitability → blocked function of language-processing networks → auditory verbal agnosia (loss of language comprehension) |
| 6. Symptoms | Loss of spoken language comprehension after normal development → regression of expressive language, auditory verbal agnosia, behavioral disorders, epileptic seizures (accompanying about 75%) |
| 7. Signs | EEG: bilateral temporal spike-and-slow waves (CSWS during sleep), normal hearing (normal auditory evoked potentials), neurological examination usually normal |
| 8. Screening | Sleep EEG (confirmation of CSWS), hearing tests (differentiation from hearing loss), language assessment, neuropsychological testing |
| 9. Diagnosis | CSWS on sleep EEG (continuous spike-and-slow waves during ≥85% of slow-wave sleep), acquired language regression, epilepsy criteria met |
| 10. Treatment | Corticosteroids (ACTH/prednisolone), antiseizure medications (valproate, clonazepam), speech therapy, multiple subpial transection (surgery) |
| 11. Prognosis | Varies with developmental age and timing of treatment; partial or complete recovery of language function possible in about 50%; the later the onset, the poorer the prognosis |
| 12. Prevention | Early diagnosis and initiation of treatment are decisive for language prognosis; consider genetic counseling within families with GRIN2A variants |
| 13. References | Landau & Kleffner Ann Neurol 1957 and 9 other papers |
Landau-Kleffner Syndrome (LKS) became known academically in 1957 when the American neurologist William M. Landau and the speech pathologist Frank R. Kleffner first described 6 cases of children with normal language development who lost language suddenly or gradually, accompanied by epileptic discharges. They named this syndrome 'acquired aphasia with convulsive disorder' and emphasized that the combination of sudden regression of previously normal language function and temporal epileptiform discharges on EEG is the key clinical feature.
Subsequently, through the 1960s~1970s, additional cases were reported from around the world, broadening the clinical spectrum, and the type of language regression (auditory verbal agnosia being the main form), the various forms of epileptic seizures and accompanying behavioral disorders were systematically described. In 1985 the ILAE (International League Against Epilepsy) officially classified LKS as an independent epilepsy syndrome, and continuous spike-and-wave during slow-wave sleep (CSWS) was subsequently established as the EEG finding key to diagnosis.
In the 2000s, the GRIN2A gene was found to be associated with LKS and related epilepsy-aphasia spectrum disorders, advancing molecular genetic understanding. GRIN2A is the gene encoding the GluN2A (NR2A) subunit of the NMDA receptor and plays an important role in synaptic plasticity of the language cortex during brain development. LKS is currently understood as the most severe phenotype of the GRIN2A-related epilepsy-aphasia spectrum disorders.
The exact cause of Landau-Kleffner syndrome has not yet been fully elucidated. Most cases are classified as idiopathic or as forms without a structural cause, occurring without a clear structural brain lesion or specific cause. However, heterozygous pathogenic variants of the GRIN2A gene are identified in about 20% of patients, and this gene is the most important known genetic cause of LKS.
The GRIN2A gene encodes the GluN2A subunit of the NMDA (N-methyl-D-aspartate) receptor, and this receptor is essential for synaptic transmission and plasticity in the temporal cortex responsible for language processing. It has been hypothesized that GRIN2A variants cause gain-of-function of the NMDA receptor, inducing hyperexcitability of the temporal cortex, which leads to sustained epileptiform discharges. However, because various phenotypes such as LKS, epilepsy with CSWS during sleep and benign rolandic epilepsy appear even within families carrying the same gene variant, factors other than the gene (modifier genes, environment, etc.) are thought to contribute to determining the phenotype.
Because associations of LKS with structural lesions (focal cortical dysplasia, post-encephalitic changes, low-grade gliomas, etc.) have also been rarely reported, it is important to exclude structural causes by brain MRI in the initial evaluation. Because autoimmune encephalitis (associated with LGI1 and CASPR2 antibodies) can cause a clinical picture similar to LKS in adults, a treatment approach different from pediatric LKS is needed in such cases.
The GRIN2A gene is located on chromosome 16p13.2 and encodes the GluN2A protein (NR2A), a core subunit of the NMDA receptor complex. The NMDA receptor is a glutamatergic ionotropic receptor that plays an essential role in neurodevelopment, synaptic plasticity (long-term potentiation), and learning and memory formation.
GRIN2A variants are expressed in the heterozygous state and show an autosomal dominant pattern of inheritance. Reported variant types include missense variants, nonsense variants, splice-site variants, small insertions/deletions and large deletions. Functionally, both loss-of-function and gain-of-function variants of the NMDA receptor have been reported, but gain-of-function variants tend to show a stronger association with the epilepsy-aphasia phenotype.
GRIN2A-related epilepsy-aphasia spectrum disorders form a continuous spectrum from the mild phenotype of benign rolandic epilepsy (BECTS) through epilepsy with continuous spike-and-wave during sleep to LKS, all sharing centrotemporal spikes during sleep and language impairment as features. Penetrance is incomplete, and various phenotypes coexist within the same family. For LKS patients without GRIN2A variants (about 80%), no other causative gene has currently been established, so diagnosis is mainly by clinical criteria.
Landau-Kleffner syndrome is a very rare disease, with only several hundred cases reported in the literature worldwide. Accurate prevalence statistics are limited, but it is estimated at fewer than 1~2 per million population. The age of onset is mostly between 2 and 12 years, with a mean age of onset of about 5~7 years. Adult onset outside this range has occasionally been reported but is very rare.
In terms of sex distribution, boys are reported to be affected about 1.5~2 times more often than girls. No particular regional concentration or ethnic predisposition is known, and it occurs sporadically around the world. A family history is observed in cases associated with GRIN2A variants, but most cases are sporadic.
The presence of epileptic seizures varies from case to case: some studies confirm epileptic seizures in about 75~80% of patients, while in others there are only EEG abnormalities without clinical seizures. Seizure types vary, including partial seizures (focal motor or sensory), generalized tonic-clonic seizures and atonic seizures.
The core pathogenesis of Landau-Kleffner syndrome is explained by the concept that sustained, repetitive epileptiform discharges arising in the temporal and parietal cortex responsible for language processing (especially Wernicke's area) directly interfere with normal processing of language networks. This is called the 'functional decortication' or 'epileptic cortical dysfunction' hypothesis.
Continuous spike-and-wave complexes (CSWS) appearing during sleep, especially in the slow-wave stage of non-REM (NREM) sleep, maintain a sustained state of hyperexcitability in cortical areas processing auditory-verbal information, so neural circuits become unable to process normal language signals. The reason language comprehension impairment (auditory verbal agnosia) appears earlier and more prominently than expressive language impairment is explained by Wernicke's language area being located closer to the center of the epileptic discharges than Broca's area.
With GRIN2A variants, overactivation of the NMDA receptor may disrupt the excitation-inhibition balance of the temporal cortex, sustaining a hyperexcitable state. It has also been hypothesized that NMDA receptor dysfunction interferes with normal synaptic pruning during brain development, inducing a state of hyperconnectivity in the language cortex. In this process, epileptic waves occurring during sleep interfere with consolidation of language memory from the daytime (memory consolidation), so previously acquired language memory may also be gradually lost.
The most central symptom of Landau-Kleffner syndrome is acquired language regression in children who had developed language normally. Language loss may appear rapidly (within days~weeks) or gradually (over months), and in some cases the course repeatedly worsens and improves in steps. Initially, impairment of language comprehension (receptive language) is most prominent, which is called auditory verbal agnosia. Patients often do not respond when their name is called or are unresponsive to familiar sounds, and are commonly mistaken for having hearing loss.
As the impairment of language comprehension progresses, expressive language also regresses, with reduced speech, reduction to single syllables and ultimately a state of mutism. However, nonverbal cognitive abilities, visuospatial abilities and motor function are mostly preserved. Epileptic seizures occur in about 75% of patients and take various forms, including partial seizures (commonly nocturnal), generalized tonic-clonic seizures, atonic seizures and atypical absence seizures.
Behavioral disorders also very commonly accompany it, and hyperactivity, aggression, anxiety, social withdrawal and autism spectrum disorder-like behaviors may appear. These behavioral changes are sometimes interpreted as a frustration response to communication difficulties caused by the language impairment, and sometimes explained by the epileptic discharges themselves affecting behavior-regulating areas. Sleep disturbances are also often reported.
The physical examination of patients with Landau-Kleffner syndrome is usually normal, and in most cases there are no signs suggesting focal neurological deficits or structural brain lesions. Hearing tests (pure-tone audiometry, speech audiometry, ABR) show no peripheral auditory abnormality, which is decisive in differentiating it from hearing loss. Auditory evoked potentials (ABR, ASSR) are normal, but abnormalities may be observed at higher stages assessing auditory processing (P300, etc.).
EEG provides the most important diagnostic sign. Unilateral or bilateral spike-and-wave complexes in the temporal or temporo-parietal regions may be observed even on awake EEG, but CSWS must be confirmed on sleep EEG. CSWS is defined as spike-and-wave complexes appearing continuously during 85% or more of NREM sleep (especially slow-wave sleep, stage 3-4). In LKS, CSWS is mainly temporal-predominant and bilateral but may be asymmetric.
Brain MRI is mostly normal. Rarely, PET (18F-FDG) shows temporal lobe hypermetabolism during sleep or hypometabolism while awake, which helps localize the epileptic cortical dysfunction. On language and neuropsychological testing, a selective decline in auditory language comprehension with relative preservation of nonverbal intelligence is characteristic.
When acquired language regression is suspected in a child, a systematic screening approach is needed to exclude epileptic causes including LKS. The most important screening test is electroencephalography (EEG) including sleep. Because CSWS can be missed with awake EEG alone, EEG during natural sleep or sleep induced with sedatives is essential. Overnight polysomnography with EEG is the most suitable for quantitatively assessing the proportion of time occupied by CSWS.
Hearing tests must be performed to exclude hearing loss, the most common differential diagnosis of language regression. A comprehensive evaluation of auditory function including pure-tone audiometry, speech audiometry and auditory brainstem response (ABR) is needed. Brain MRI (including gadolinium contrast) is performed to exclude structural causes such as focal cortical dysplasia, glioma and post-encephalitic scarring.
Formal language assessment by a speech-language pathologist (quantification of receptive and expressive language abilities) and neuropsychological testing (cognitive function, attention, behavior) are essential components of the screening process. Testing for autoimmune encephalitis antibodies (LGI1, CASPR2, AMPA-R, GABA-B-R, NMDA-R, etc.) is performed in serum and cerebrospinal fluid to exclude or confirm an immune-mediated mechanism. GRIN2A genetic testing is considered when a genetic cause is suspected, especially when there is a family history.
The diagnosis of Landau-Kleffner syndrome requires meeting both clinical criteria and EEG criteria. The main diagnostic criteria presented by the International League Against Epilepsy (ILAE) and the literature are as follows.
First, acquired regression of language function in a child who had shown normal neurological and language development. The language regression centers on auditory verbal agnosia (impaired language comprehension) and may be accompanied by expressive language impairment. The language regression must persist for at least 3 months and must not be explained by other causes (hearing loss, structural brain lesions, progressive neurodegenerative diseases). Second, confirmation of a CSWS pattern on sleep EEG: temporal-predominant spike-and-wave complexes appearing continuously in ≥85% of NREM sleep; or epileptiform discharges in the temporal/temporo-parietal regions on awake or sleep EEG. Third, epileptic seizures, if present (about 75%), are not an essential element for diagnosis.
In the differential diagnosis, autism spectrum disorder, auditory processing disorder, nonsyndromic language disorder, autoimmune encephalitis and neurodegenerative diseases (AIDS-related neuropathy, mitochondrial disease, etc.) must be excluded. A positive GRIN2A genetic test supports the diagnosis, but a negative result does not exclude the diagnosis if the clinical and EEG criteria are met.
The goal of treatment for Landau-Kleffner syndrome is to suppress epileptiform discharges and CSWS to promote recovery of language function. There are currently no standardized treatment guidelines, but strategies based on clinical experience and the results of small studies are used.
Corticosteroids (adrenocorticotropic hormone, ACTH, or high-dose prednisolone) are known as one of the most effective treatments for improving language function in LKS. The mechanism is explained by suppression of epileptiform discharges together with modulation of immune-mediated inflammatory responses. The treatment response may appear within days to weeks, but because relapse is common during steroid tapering, a long-term administration strategy (low-dose maintenance therapy) is often needed. Prednisolone is started at 1~2 mg/kg/day and tapered gradually, and monitoring for adverse effects (obesity, growth inhibition, hypertension, osteoporosis, susceptibility to infection) is essential.
Antiseizure medication monotherapy is effective in controlling epileptic seizures but often does not show as much effect as steroids on recovery of language function. Sodium valproate, clonazepam, levetiracetam and sulthiame are used. As an important precaution, carbamazepine, oxcarbazepine, phenytoin and phenobarbital should be avoided because they can worsen CSWS. Clonazepam is used clinically as one of the drugs effective in suppressing CSWS.
Multiple subpial transection (MST) is a surgical method that blocks epileptiform discharges while preserving the function of the language cortex as much as possible in patients with refractory LKS that does not respond to medical treatment. MST works by severing horizontal synaptic connections in the language cortex (Wernicke's area, Heschl's gyrus) to suppress epileptic propagation, and meaningful recovery of language function has been reported in some patients. Surgery is indicated when CSWS is clearly localized and there is potential for recovery of language function.
Intensive speech-language therapy is essential in combination with medical treatment to promote recovery of language function. Use of sign language and augmentative and alternative communication (AAC) tools also helps maintain communication ability. Psychiatric support for managing behavioral disorders and adjustment of the educational environment are also important.
The language prognosis of Landau-Kleffner syndrome is quite heterogeneous. In some patients, language function recovers substantially or completely around puberty, spontaneously or in response to treatment, whereas in others permanent language impairment persists into adulthood. Overall, about 50% of patients are reported to experience some degree of recovery of language function.
The most important factors affecting language prognosis are the age of onset and the time to diagnosis and initiation of treatment. The younger the age of onset (especially before age 5), the longer the duration of language impairment and the later the treatment, the poorer the prognosis. Conversely, when the age of onset is later (after age 8) and steroid treatment is started promptly after detection, the likelihood of complete recovery of language function is higher. Epileptic seizures themselves mostly disappear before puberty, so persistence of epilepsy into adulthood is rare.
The shorter the duration of CSWS and the earlier the EEG findings normalize, the better the language prognosis. In the long term, some patients may have persistent residual symptoms such as impaired executive function, attention disorders, learning disabilities and difficulties in social communication. Continued educational support and vocational rehabilitation are important for maintaining quality of life in adulthood.
There is currently no direct preventive method to stop the onset of Landau-Kleffner syndrome itself. However, early detection and prompt treatment are the most important 'preventive' approach to minimizing damage to language function. In children with language regression, first excluding hearing loss, diagnosing LKS early by EEG and promptly starting steroid treatment are directly linked to improved language prognosis.
Genetic counseling is recommended for families with GRIN2A-related epilepsy-aphasia spectrum disorders, and families should be educated to have immediate neurological evaluation and EEG performed if signs of language developmental delay or regression appear in children in the family. Raising awareness of LKS among pediatricians, speech-language pathologists and otolaryngologists is a key strategy to reduce diagnostic delay.
Even in patients whose epileptic seizures are well controlled and whose language function has recovered, stress, sleep deprivation, infections, etc. can trigger relapse, so they are guided to maintain regular sleep and healthy lifestyle habits. Providing appropriate special education support and communication aids in school and educational settings contributes to improving functional prognosis.